An enzyme identified in Saccharomyces cerevisiae, commonly known as brewer's or baker's yeast, has passed in vitro trials, demonstrating its capacity to kill acute lymphoblastic leukemia (ALL) cells.
New research has found concussions accelerate Alzheimer's disease-related brain atrophy and cognitive decline in people who are at genetic risk for the condition.
The findings, which appear in the journal Brain, show promise for detecting the influence of concussion on neurodegeneration.
The mechanical resistance of tumors and collateral damage of standard treatments often hinder efforts to defeat cancers. However, a team of researchers from the CNRS, the French National Institute of Health and Medical Research (INSERM), Paris Descartes University, and Paris Diderot University has successfully softened malignant tumors by heating them. This method, called nanohyperthermia, makes the tumors more vulnerable to therapeutic agents.
[adsense:336x280:8701650588]
In a small double-blind study, Johns Hopkins researchers report that a substantial majority of people suffering cancer-related anxiety or depression found considerable relief for up to six months from a single large dose of psilocybin -- the active compound in hallucinogenic "magic mushrooms."
More than 2 million people got infected by human immunodeficiency virus (HIV) in 2015, being sexual transmission the main channel of infection. Researchers from the Infections of the Respiratory Tract and in Immunocompromised Patients group of the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Daniel Podzamczer, have evaluated the speed at which a new antiretroviral drug, Dolutegravir, is able to reduce the viral load in semen, an area of the body considered to be a reservoir of the virus and where access for drugs is more difficult. The results, published in Journal of Infectious Diseases, show the potential of these new treatments to reduce the chances of sexual transmission of the virus.
Pembrolizumab (trade name: Keytruda) was initially introduced for the treatment of melanoma. Since July 2016, the monoclonal antibody has also been available for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults whose tumours express the T-cell receptor ligand PD-L1 and who have received a prior chemotherapy regimen. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether the drug offers an added benefit over the appropriate comparator therapy also for these patients.
INDIANAPOLIS - A combination of the stimulant drug methylphenidate with a process known as cognitive-behavioral rehabilitation is a promising option to help people who suffer from persistent cognitive problems following traumatic brain injury, researchers at Indiana University School of Medicine have reported.
Scientists from the National Institutes of Health have identified an antibody from an HIV-infected person that potently neutralized 98 percent of HIV isolates tested, including 16 of 20 strains resistant to other antibodies of the same class. The remarkable breadth and potency of this antibody, named N6, make it an attractive candidate for further development to potentially treat or prevent HIV infection, say the researchers.
An experimental kidney cancer drug outperformed the standard first-line therapy for patients with metastatic disease who are considered at risk for poorer than average outcomes, according to results of a randomized phase II clinical trial by researchers at Dana-Farber Cancer Institute.
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
